Advisors Preferred, LLC Halozyme Therapeutics, Inc. Transaction History
Advisors Preferred, LLC
- $718 Million
- Q1 2025
A detailed history of Advisors Preferred, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Advisors Preferred, LLC holds 55,536 shares of HALO stock, worth $3.28 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
55,536
Previous 42,162
31.72%
Holding current value
$3.28 Million
Previous $2.02 Million
75.83%
% of portfolio
0.49%
Previous 0.33%
Shares
11 transactions
Others Institutions Holding HALO
# of Institutions
585Shares Held
122MCall Options Held
308KPut Options Held
131K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$758 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$357 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$230 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$217 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.23B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...